2024-10-19 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis

This report analyzes AbbVie Inc. (ABBV), a leading biopharmaceutical company developing and marketing therapies in various therapeutic areas.

### 1. Performance Comparison with S&P 500 (VOO)

**ABBV** has outperformed the S&P 500 (VOO) with a cumulative return of **145.09%** compared to VOO's **136.97%**.  This translates to a **8.12%** difference in performance. 

The **relative divergence** of **50.35%** indicates that ABBV has outperformed VOO more than 50% of the time based on historical data.

### 2. Recent Price Movement

| Indicator | Value |
|---|---|
| Closing Price | 188.57 |
| 5-Day Moving Average | 192.15 |
| 20-Day Moving Average | 193.84 |
| 60-Day Moving Average | 192.92 |

ABBV's current price is below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term downtrend. 

### 3. Technical Indicators

| Indicator | Value | Interpretation |
|---|---|---|
| RSI | 32.5 | Below 50, indicating oversold conditions |
| PPO | -0.37 | Negative value suggests potential for further downside |
| Delta_Previous_Relative_Divergence | -9.83 | Negative value indicating a short-term downtrend in relative divergence |
| Expected Return | 1.94% | ABBV is expected to outperform the S&P 500 (VOO) by 1.94% over the next 5 years |

### 4. Recent Earnings and Outlook

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV's most recent earnings report for the quarter ending July 25, 2024, showed **EPS of 2.65**, exceeding the expected EPS of **2.57**. The company has consistently exceeded earnings expectations in recent quarters.

### 5. News and Recent Issues

* Recent market outlook for ABBV remains positive, with analysts citing the company's strong portfolio of products, particularly Humira, as a key driver of growth.
* **FINBOLD** reports that **ABBV's stock is undervalued** and has **potential for growth** due to its **strong pipeline of new drugs**. 
* **Analyst opinions** are largely positive, with many predicting **continued growth and profitability**. 

### 6. Overall Analysis

ABBV has consistently outperformed the S&P 500 (VOO) and currently trades in oversold territory. While recent price movements suggest a short-term downtrend, technical indicators and strong earnings performance suggest a potential for future growth.  The company's robust portfolio of products, strong pipeline, and positive analyst sentiment offer further support for long-term investment.

### 7. Summary

ABBV is a promising biopharmaceutical company with a strong track record of performance. Despite recent short-term downtrends, its strong fundamentals and positive outlook suggest potential for continued growth.  Investors seeking long-term exposure to the healthcare sector may consider adding ABBV to their portfolio. 
